Clinical Trial

French Colorectal ESD Cohort in Experts Centers

Study acronym: FECCo
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 15, 2025 (before its estimated January 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Initially developed in Japan for the treatment of endemic superficial gastric cancers, endoscopic submucosal dissection (ESD) allows resection of pre-neoplastic and neoplastic lesions of the digestive tract into a single fragment. It allows a perfect pathological analysis, and decreases the rate of recurrence of the adenoma to less than 2%. However, this procedure, which is technically more challenging, is also more risky (perforation rate at 4% vs. 1% for WF-EMR) and longer. Submucosal dissection is also more expensive in terms of equipment, but this difference can be offset by the cost of the high number of iterative colonoscopies required in patients who have had endoscopic resection by WF-EMR. Scientific debate is agitating the Western world1,2 and Japanese experts do not perform WF-EMR anymore, whereas no comparative prospective study has compared these two procedures. A lot of centers in France performed colorectal ESD even for benign lesions and nationwide data about safety and efficiency is required to confirm the place of ESD for treatment of large superficial colorectal lesions. The aim of this French multicenter cohort is to analyze the results of colorectal submucosal dissection on a large scale.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2020-10-12.
Trial Details
NCT Number NCT04592003
Lead Sponsor University Hospital, Limoges
Conditions Cancer Colorectal, Polyps Colorectal, Endoscopic Submucosal Resection
Enrollment 1,200 participants
Start Date 2020-01-01
Primary Completion 2026-01-01 (estimated)
Study Completion 2026-01-01 (estimated)
Updated on ClinicalTrials.gov 2025-09-15